Concepedia

Ina Landel

IL

6

Publications

347

Citations

6

H-Index

2019

Active since

Affiliations

TU Dortmund University(Current)

German Cancer Research Center

Heidelberg University

Lead Discovery Center (Germany)

Deutschen Konsortium für Translationale Krebsforschung

Ina Landel is an author at TU Dortmund University specializing in medicine, drug discovery, and medicinal chemistry.

Top concepts

MedicineBiochemistryPharmacologyDrug DiscoveryPharmacotherapyNatural SciencesMedicinal ChemistryMolecular PharmacologyApoptosisCell Death

Publications per year

2019–2022

6

Publications

6

Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in <i>KRAS</i>-Mutant Pancreatic and Colorectal Cancer

Jörn Weisner, Ina Landel, Christoph Reintjes et al. · Cancer Research · 2019 · 88 citations

Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity

Lena Quambusch, Ina Landel, Laura Depta et al. · Angewandte Chemie International Edition · 2019 · 69 citations · Full text

Molecular Docking, Molecular Pharmacology, Medicinal Chemistry +15

Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt

Niklas Uhlenbrock, Steven P. Smith, Jörn Weisner et al. · Chemical Science · 2019 · 65 citations · Full text

Molecular Biology, Chemical Biology, Pharmaceutical Chemistry +18

Spotlight on AKT: Current Therapeutic Challenges

Ina Landel, Lena Quambusch, Laura Depta et al. · ACS Medicinal Chemistry Letters · 2020 · 52 citations · Full text

Apoptosis, Immunology, Cell Death +22

Cellular model system to dissect the isoform-selectivity of Akt inhibitors

Lena Quambusch, Laura Depta, Ina Landel et al. · Nature Communications · 2021 · 50 citations · Full text

Rows per page

1–5 of 6